EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma

Simona Andrea Ruckstuhl, Katja Seipel iD, Inna Shaforostova, Martina Bertschinger iD, Ulrike Bacher iD, Thomas Pabst iD

Cancers · 29.06.2026 · 18 (13) · 2110

DOI: 10.3390/cancers18132110 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 29.06.2026. Verfasst von Simona Andrea Ruckstuhl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Brexu-cel is an established CD19-directed CAR-T cell therapy for relapsed or refractory mantle cell lymphoma, but clinical outcomes are heterogeneous, and germline determinants of response are poorly defined.

Methods

We investigated the clinical impact of the CD19 single-nucleotide polymorphism rs2904880 on treatment outcome after brexu-cel CAR-T cell therapy by analyzing genotype-outcome associations in a retrospective single-center cohort of patients with relapsed or refractory mantle cell lymphoma treated with this CAR-T cell therapy.

Results

Overall survival varied according to CD19 polymorphism, with improved survival of patients carrying the V174 homozygous genotype compared with L174V heterozygotes.

Conclusions

The germline CD19 polymorphism may have implications for future risk stratification after brexu-cel CAR-T cell therapy in mantle cell lymphoma, but requires validation in larger, multicenter cohorts.

Schlagwörter

Stichwörter der Autor:innen

chimeric antigen receptor (CAR)mantle cell lymphoma (MCL)overall survival (OS)progression-free survival (PFS)single-nucleotide polymorphism (SNP)

Autor:innen und Institutionen

  • Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.
  • Department for Biomedical Research (DBMR), University of Bern, 3008 Bern, Switzerland.
  • Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.

ORCID-Profile: Katja Seipel, Martina Bertschinger, Ulrike Bacher, Thomas Pabst

Zitieren

APA

Ruckstuhl, S. A., Seipel, K., Shaforostova, I., Bertschinger, M., Bacher, U., & Pabst, T. (2026). Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma. Cancers, 18(13), 2110. https://doi.org/10.3390/cancers18132110

Vancouver

Ruckstuhl SA, Seipel K, Shaforostova I, Bertschinger M, Bacher U, Pabst T. Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma. Cancers. 2026;18(13):2110. doi:10.3390/cancers18132110

BibTeX
@article{Ruckstuhl2026,
  author = {Ruckstuhl, Simona Andrea and Seipel, Katja and Shaforostova, Inna and Bertschinger, Martina and Bacher, Ulrike and Pabst, Thomas},
  title = {Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {13},
  pages = {2110},
  doi = {10.3390/cancers18132110}
}
Kostenlos starten →